
@ShahidNShah
Kelonia Therapeutics focused on vivo gene delivery, launched with a $50M in funding to expand the benefit and reach of genetic medicines.
What You Should Know:
– Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines.
– Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and dose-limiting toxicities. By enabling precisely targeted, highly efficient, manufacturable “off-the-shelf” in vivo gene delivery, Kelonia’s technology has the potential to dramatically expand the impact and reach of genetic medicines to every patient in need.
Continue reading at hitconsultant.net
Dr. Liz Kwo outlines the landscape of the RPM space. Used at the beginning of the pandemic mainly in the form of videoconferences and telemedicine, remote patient monitoring (RPM) is currently adopted …
Posted May 2, 2022 Remote Patient Monitoring Telehealth
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2025 Netspective Foundation, Inc. All Rights Reserved.
Built on Feb 10, 2025 at 1:27pm